DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 7.61

Change

+0.04 (+0.53)%

Market Cap

USD 0.17B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares IND..

+0.02 (+0.02%)

USD 18.39B
IVV:AU Ishares S&P 500 ETF

-0.38 (-0.62%)

USD 11.33B
VGS:AU Vanguard MSCI INDEX Internatio..

-0.72 (-0.51%)

USD 10.39B
QUAL:AU Vaneck MSCI International Qual..

+0.01 (+0.02%)

USD 7.35B
IOZ:AU Ishares Core S&P/ASX 200 ETF

-0.01 (-0.03%)

USD 6.40B
VTS:AU Vanguard US Total Market Share..

-2.77 (-0.61%)

USD 5.71B
STW:AU SPDR S&P/ASX 200 ETF

-0.05 (-0.06%)

USD 5.54B
NDQ:AU Betashares Nasdaq 100 ETF

-0.22 (-0.44%)

USD 5.22B
HNDQ:AU Betashares Nasdaq 100 Currency..

+0.08 (+0.18%)

USD 4.86B
A200:AU Betashares Australia 200 ETF

N/A

USD 4.72B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.18% 14% F 46% F
Dividend Return 0.35% 10% F 6% D-
Total Return -2.83% 13% F 44% F
Trailing 12 Months  
Capital Gain -12.53% 4% F 41% F
Dividend Return 2.88% 40% F 31% F
Total Return -9.65% 3% F 41% F
Trailing 5 Years  
Capital Gain 14.26% 35% F 60% D-
Dividend Return 10.99% 24% F 22% F
Total Return 25.25% 28% F 57% F
Average Annual (5 Year Horizon)  
Capital Gain 5.20% 59% D- 56% F
Dividend Return 7.15% 59% D- 56% F
Total Return 1.95% 54% F 38% F
Risk Return Profile  
Volatility (Standard Deviation) 8.56% 61% D- 91% A-
Risk Adjusted Return 83.53% 73% C 91% A-
Market Capitalization 0.17B 32% F 64% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.